The US FDA has granted approval for AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for ...

AstraZeneca's cancer drug, datopotamab deruxtecan, failed to meet targets in a Phase 3 trial, clouding the possibility of approval from the U.S. Food and Drug Administration. Shares were down 1.2% at ...

Board members from the European Central Bank are set to speak through the week, with Frank Elderson and Piero Cipollone ...

The AJ is delighted to announce the finalists of this year’s AJ Architecture Awards. The first to be revealed are in the ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan ...

It’s goodbye needles as you can keep the flu away with a nasal spray as the US Food and Drug Administration (FDA) has approved AstraZeneca’s FluMist for home use. It can be self-administered by adults ...

Among the companies with reports and trading updates today are Rightmove, Galliford Try, Oxford Biomedica, AstraZeneca, ...

BNP Paribas has agreed to buy the private banking activities of HSBC in Germany, saying the deal would grow is exposure to entrepreneurs in the country. The eurozone’s biggest bank did not disclose ...

AstraZeneca's breast cancer drug datopotamab deruxtecan didn't show a statistical significance in overall survival compared with chemotherapy, results showed at a phase three trial.

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...